Iksuda CEO says British biotech is buoyant, Brexit notwithstanding

23 October 2019

In March 2019, after a series of political convolutions worthy of a Choose Your Own Adventure novel, former UK Prime Minister Theresa May finally managed to bring her country, and its complaining industries, to the brink of Brexit.

Her efforts failed, and Brexit has since been delayed twice. This week, new Prime Minister Boris Johnson grudgingly requested a further delay, opening up the prospect of yet more “Brexit purgatory” for business leaders.

Pharma investors and others with an interest in the success of the UK’s otherwise blossoming biotech and pharma sectors have watched aghast, as the country’s political system has appeared to self destruct over the issue.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK